Repositorio Dspace

Textbook outcome in ovarian cancer and its impact on survival: comparative study

Mostrar el registro sencillo del ítem

dc.contributor.author Carbonell-Morote, Silvia
dc.contributor.author Arjona-Sánchez, Álvaro
dc.contributor.author Cascales-Campos, Pedro-Antonio
dc.contributor.author González-Gil, Alida
dc.contributor.author Gómez-Dueñas, Gonzalo
dc.contributor.author Gil-Gómez, Elena
dc.contributor.author Caravaca-García, Iban
dc.contributor.author Aranaz, Veronica
dc.contributor.author Lacueva, Francisco-Javier
dc.contributor.author Ramia, José-Manuel
dc.date.accessioned 2026-03-06T14:24:28Z
dc.date.available 2026-03-06T14:24:28Z
dc.date.issued 2025-02-01
dc.identifier.citation Carbonell-Morote S, Arjona-Sánchez A, Cascales-Campos PA, González-Gil A, Gomez-Dueñas G, Gil-Gómez E, et al. Textbook outcome in ovarian cancer and its impact on survival: comparative study. World J Surg Onc. 1 de febrero de 2025;23(1):32. doi:10.1186/s12957-025-03686-5
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/24869
dc.description.abstract INTRODUCTION: Patients who achieve the textbook outcome (TO) present an uneventful postoperative course. Obtaining TO has also been related to better survival in oncological patients. Information about TO in patients with peritoneal carcinomatosis from ovarian cancer who undergo surgery is very scarce. Our objective was investigate TO in patients with carcinomatosis of ovarian origin who underwent interval surgery with or without HIPEC (TOOC) and its impact on survival. METHODS: A multicenter study was performed between 2010 and 2015. Inclusion criteria were > 18 years old, with ovarian cancer and peritoneal carcinomatosis, who underwent scheduled surgery after response to neoadjuvant therapy. The criteria to establish TOOC were no major complications, no mortality, non-prolonged stay (p75:10 days), complete cytoreduction (CC-0), and no readmission. RESULTS: 365 patients were included, and TOOC was achieved in 204 (55.9%) patients. CC-0 cytoreduction was obtained in 312(85.5%). 7 patients (1.9%) died. 71 (19.5%) presented major complications (? IIIa). The readmission rate was 9.3%, and 24.9% of the patients presented a prolonged stay. The parameter with most significant negative impact on achieving TOOC was length of stay. Multivariate analysis confirmed postsurgical PCI, age, HIPEC, and time of surgery in minutes as an independent factor of TOOC. Survival analysis showed that patients who achieved TOOC had better overall survival (41 months (24.5- 67) versus 27 months (14-48.2) (p < 0.0001). CONCLUSION: TO is an easy and valuable management tool for evaluating and comparing results obtained at different centers after surgery for peritoneal carcinomatosis of locally advanced ovarian cancer. Achieving TOOC benefits overall survival.
dc.language.iso eng
dc.publisher BMC
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject.mesh Humans
dc.subject.mesh Female
dc.subject.mesh Ovarian Neoplasms/mortality/pathology/therapy/surgery
dc.subject.mesh Middle Aged
dc.subject.mesh Cytoreduction Surgical Procedures/mortality
dc.subject.mesh Peritoneal Neoplasms/mortality/secondary/therapy/surgery
dc.subject.mesh Survival Rate
dc.subject.mesh Aged
dc.subject.mesh Adult
dc.subject.mesh Prognosis
dc.subject.mesh Follow-Up Studies
dc.subject.mesh Hyperthermic Intraperitoneal Chemotherapy/mortality
dc.subject.mesh Neoadjuvant Therapy/mortality
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Retrospective Studies
dc.subject.mesh Treatment Outcome
dc.subject.mesh Postoperative Complications
dc.title Textbook outcome in ovarian cancer and its impact on survival: comparative study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 39893428
dc.relation.publisherversion https://wjso.biomedcentral.com/articles/10.1186/s12957-025-03686-5
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1186/s12957-025-03686-5
dc.journal.title World Journal of Surgical Oncology
dc.identifier.essn 1477-7819


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta